P&G Intrinsa Need For Longer-Term Safety Data To Be Examined By Reproductive Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask committee whether Intrinsa testosterone patch needs more safety data in women receiving estrogen prior to approval. Procter & Gamble is proposing a pharmacovigilance study to follow emerging adverse events with the female sexual dysfunction drug.
You may also be interested in...
P&G Intrinsa Gets No Satisfaction; Potential Risks Outweigh Sexual Benefits
FDA’s Reproductive Health Drugs Advisory Committee votes unanimously Dec. 2 that current efficacy and safety data for the female sexual dysfunction therapy do not support approval. Committee recommends completion of safety studies in pre- and postmenopausal women prior to approval.
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.